Related Experiment Video
Updated: Aug 25, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types
Lydia J Atherton1, Patricia A Jorquera1, Abhijeet A Bakre1
1Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.
Insights
MicroRNAs (miRs) show promise as biomarkers for Respiratory Syncytial Virus (RSV) vaccine development. These miRs correlate with immune responses, aiding in assessing the safety and efficacy of new RSV vaccines.
Area of Science:
- * Virology
- * Immunology
- * Molecular Biology
Background:
- * Respiratory Syncytial Virus (RSV) causes severe respiratory illness in infants, young children, and the elderly.
- * Current RSV vaccine development is hindered by a lack of safety and efficacy biomarkers.
- * MicroRNAs (miRs) are being investigated as potential diagnostic and prognostic markers.
Purpose of the Study:
- * To identify microRNAs (miRs) that can serve as biomarkers for Respiratory Syncytial Virus (RSV) vaccine candidates.
- * To assess the relationship between miR expression profiles and immunological responses to different RSV vaccine types.
- * To evaluate the potential of miRs in predicting vaccine-induced protection and safety.
Main Methods:
- * Mice were vaccinated with different RSV vaccine candidates: live attenuated (CP52), G protein microparticle (GA2-MP), and formalin-inactivated (FI-RSV).
- * Immunological endpoints were measured in serum and bronchoalveolar lavage (BAL) fluid.
- * microRNA (miR) expression profiles were analyzed in serum and BAL fluid post-vaccination and RSV challenge.
Main Results:
- * Specific microRNAs (miRs) were identified and linked to immunological parameters associated with disease and protection.
- * Distinct miR expression patterns were observed in response to different RSV vaccine types.
- * These miRs provide insights into the immune response elicited by RSV vaccine candidates.
Conclusions:
- * microRNAs (miRs) are potential biomarkers for assessing the safety and efficacy of Respiratory Syncytial Virus (RSV) vaccines.
- * miR profiling can offer valuable information for the development of effective RSV vaccines.
- * Further research is warranted to validate these miRs in clinical settings.
Abstract:
Respiratory Syncytial Virus (RSV) causes serious respiratory tract illness and substantial morbidity and some mortality in populations at the extremes of age, i.e., infants, young children, and the elderly. To date, RSV vaccine development has been unsuccessful, a feature linked to the lack of biomarkers available to assess the safety and efficacy of RSV vaccine candidates. We examined microRNAs (miR) as potential biomarkers for different types of RSV vaccine candidates. In this study, mice were vaccinated with a live attenuated RSV candidate that lacks the small hydrophobic (SH) and attachment (G) proteins (CP52), an RSV G protein microparticle (GA2-MP) vaccine, a formalin-inactivated RSV (FI-RSV) vaccine or were mock-treated. Several immunological endpoints and miR expression profiles were determined in mouse serum and bronchoalveolar lavage (BAL) following vaccine priming, boost, and RSV challenge. We identified miRs that were linked with immunological parameters of disease and protection. We show that miRs are potential biomarkers providing valuable insights for vaccine development.
